Does preemptive gabapentin modulate cytokine response in total knee arthroplasty? A placebo controlled study

Area of Science:

• Anesthesiology and Pain Management
• Pharmacology
• Immunology

Background:

• Gabapentin, a gabapentinoid, is explored for postoperative pain management.
• Its efficacy in total knee arthroplasty (TKA) requires further investigation.

Purpose of the Study:

• To evaluate preemptive oral gabapentin (800 mg) versus placebo for postoperative pain and inflammatory markers in TKA patients.
• To assess the impact on pain scores, analgesic needs, and cytokine levels (IL-6, TNF-R).

Main Methods:

• Randomized, double-blind study with 52 TKA patients.
• Gabapentin or placebo administered 1 hour pre-surgery.
• Standard general anesthesia and intraoperative diclofenac sodium.
• Postoperative pain assessed via Visual Analogue Scale (VAS) and analgesic use.
• Plasma IL-6 and TNF-R levels measured at baseline, 4h, and 24h post-op.

Main Results:

• No significant difference in VAS pain scores or additional analgesic requirements between groups.
• Gabapentin group showed significantly lower IL-6 levels at 4h and 24h post-op compared to placebo.
• No significant difference in TNF-R levels between the gabapentin and placebo groups.

Conclusions:

• Preemptive gabapentin did not reduce postoperative pain or analgesic needs in TKA.
• Gabapentin administration attenuated IL-6 production on the first postoperative day.
• Further research may explore gabapentin's role in modulating the inflammatory response post-TKA.